How to manage monoclonal gammopathy of undetermined significance (MGUS)
Niels van de Donk
How do we sequence and combine novel agent-based therapies in CLL?
Advancements in APL treatment: oral ATO, MRD and treatment objectives
CLL update from ICML17: Current treatment and future directions for patients
Novel agents for myeloma related bone disease